p300 in prostate cancer proliferation and progression.

Although prostate cancer (PCa) is the most frequently diagnosed cancer in males, little is known about the mechanisms involved in its progression. Recent in vitro studies suggest that coactivators of the androgen receptor play an important role in PCa progression. We have shown previously that p300 is involved in androgen receptor transactivation. In the present work, we studied 95 patients with biopsy-proven PCa who underwent prostatectomy as treatment of their tumors between 1995 and 1998. We found that p300 correlated with in vivo proliferation (P = 0.009) as determined by MIB-I expression. Moreover, high levels of p300 in biopsies predicted larger tumor volumes (P < 0.001), extraprostatic extension (P = 0.003), and seminal vesicle involvement (P = 0.002) at prostatectomy, as well as PCa progression after surgery (P = 0.01). Furthermore, we found that the disruption of p300 transcripts through small interfering RNA inhibited PCa cell proliferation both at the basal level and on interleukin 6 stimulation. We conclude that p300 plays an important role in PCa cell proliferation, as well as PCa progression.

[1]  J. Cheville,et al.  Predicting prostate carcinoma volume and stage at radical prostatectomy by assessing needle biopsy specimens for percent surface area and cores positive for carcinoma, perineural invasion, Gleason score, DNA ploidy and proliferation, and preoperative serum prostate specific antigen , 2001 .

[2]  F. Martelli,et al.  MyoD Stimulates RB Promoter Activity via the CREB/p300 Nuclear Transduction Pathway , 2003, Molecular and Cellular Biology.

[3]  T. Iwama,et al.  p300 gene alterations in colorectal and gastric carcinomas. , 1996, Oncogene.

[4]  Xin Yu,et al.  Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. , 2002, The American journal of pathology.

[5]  D. Tindall,et al.  The role of androgens and the androgen receptor in prostate cancer. , 2002, Cancer letters.

[6]  J. Cheville,et al.  Metastatic prostate carcinoma to bone , 2002, Cancer.

[7]  R. Mantovani,et al.  Cyclin B1 transcription is enhanced by the p300 coactivator and regulated during the cell cycle by a CHR‐dependent repression mechanism , 2003, FEBS letters.

[8]  D. Tindall,et al.  p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. , 2002, Cancer research.

[9]  M. Erdos,et al.  p300 Modulates the BRCA1 inhibition of estrogen receptor activity. , 2002, Cancer research.

[10]  D. Tindall,et al.  Androgen receptor signaling in androgen-refractory prostate cancer. , 2001, Journal of the National Cancer Institute.

[11]  H. Klocker,et al.  The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function. , 2003, The American journal of pathology.

[12]  J. Cheville,et al.  Perineural Invasion and MIB-1 Positivity in Addition to Gleason Score Are Significant Preoperative Predictors of Progression After Radical Retropubic Prostatectomy for Prostate Cancer , 2002, The American journal of surgical pathology.

[13]  P. Cole,et al.  Down-regulation of p300/CBP histone acetyltransferase activates a senescence checkpoint in human melanocytes. , 2002, Cancer research.